BioCryst Pharmaceuticals, Inc.

How big is BioCryst Pharmaceuticals, Inc.?

As of Jun 18, BioCryst Pharmaceuticals, Inc. has a market capitalization of $2.09 billion, with recent net sales of $503.47 million and a net profit of -$53.47 million. As of Dec 24, the company reported shareholder's funds of -$475.93 million and total assets of $490.42 million.

Market Cap: As of Jun 18, BioCryst Pharmaceuticals, Inc. has a market capitalization of 2,086.23 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, BioCryst Pharmaceuticals reported net sales of 503.47 million and a net profit of -53.47 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -475.93 million and total assets of 490.42 million.

What does BioCryst Pharmaceuticals, Inc. do?

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing small molecule drugs for rare diseases. It has a market cap of approximately $2.09 billion, with recent net sales of $146 million and no net profit.

Overview:<BR>BioCryst Pharmaceuticals, Inc. is a biotechnology company that designs, optimizes, and develops small molecule drugs targeting enzymes involved in the pathogenesis of diseases, focusing on the treatment of rare diseases. It operates within the Pharmaceuticals & Biotechnology industry and falls under the micro-cap market category.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 146 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,086.23 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.16 <BR>Return on Equity: 11.83% <BR>Price to Book: -4.62 <BR><BR>Contact Details:<BR>Address: 4505 Emperor Blvd Ste 200, DURHAM NC: 27703-8457 <BR>Tel: 1 919 8591302 <BR>Fax: 1 919 8591314 <BR>Website: https://www.biocryst.com/

Should I buy, sell or hold BioCryst Pharmaceuticals, Inc.?

Who are in the management team of BioCryst Pharmaceuticals, Inc.?

As of March 2022, the management team of BioCryst Pharmaceuticals, Inc. includes Robert Ingram (Independent Chairman), Jon Stonehouse (CEO), and several independent directors: George Abercrombie, Stephen Aselage, Theresa Heggie, Nancy Hutson, and Kenneth Lee. They oversee the company's strategic direction and operations.

As of March 2022, the management team of BioCryst Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Robert Ingram, Independent Chairman of the Board<BR>- Mr. Jon Stonehouse, President, Chief Executive Officer, Director<BR>- Mr. George Abercrombie, Independent Director<BR>- Mr. Stephen Aselage, Independent Director<BR>- Ms. Theresa Heggie, Independent Director<BR>- Dr. Nancy Hutson, Independent Director<BR>- Mr. Kenneth Lee, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is BioCryst Pharmaceuticals, Inc. technically bullish or bearish?

As of October 3, 2025, BioCryst Pharmaceuticals, Inc. is in a bearish trend, indicated by negative MACD readings, bearish Bollinger Bands, and underperformance against the S&P 500, with a year-to-date return of -6.65% compared to the S&P's 14.18%.

As of 3 October 2025, the technical trend for BioCryst Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators including bearish readings on the MACD for both weekly and monthly time frames, bearish Bollinger Bands, and a bearish daily moving average. The Dow Theory indicates a mildly bearish stance on both weekly and monthly levels. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a 1-week return of -7.02% compared to the S&P 500's 1.09%, and a year-to-date return of -6.65% versus the S&P 500's 14.18%.